2Seventy Bio Inc

2Seventy Bio — Investor Presentation (August 2022)

33 slides from 2Seventy Bio's investor presentation, Aug 10, 2022

  1. Slide 1: Join the Patient Mission

    Join the Patient Mission Company Presentation August 2022

  2. Slide 2: Cautionary note regarding forward-looking statements

    Cautionary note regarding forward-looking statements 2 These slides and the accompanying oral presentation may contain “forward-looking statements”. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, m

  3. Slide 3: It's about time™ Time Geeks

    3 It’s about time™ Time Geeks The most committed and passionate geeks driving next gen oncology cell therapeutics

  4. Slide 4: Key launch ingredients and plans years in the making

    Key “launch” ingredients and plans 4 12 years in the making ABECMA® Deliver to patients and scale to demand NextGen Potential Proof-of-Concept Test, learn & iterate in the clinic Disrupt Relentless innovation – science, medicine & manufacturing Product Engine Double Down Science, translation, capabi

  5. Slide 5: Horizons focused on long term learning and disruption

    Horizons focused on long term learning and disruption 5 Horizon 0: Launch Company Horizon 1: ABECMA® Horizon 2: Clinical Pipeline Horizon X: Disrupt Spin & Double Down Launch & Scale Liquid Tumors: B-NHL & AML Deep Deep Auto (Very Angry T cell) Focus Team & Burn 3rd Line & Beyond Solid Tumors: MUC16

  6. Slide 6: 2022 Goals – Transformative build & deliver year

    2022 Goals – Transformative build & deliver year 6 Cash Runway into 2025 Deliver ABECMA® Amp Up Product Engine Tune Burn + Capabilities Anticipated $250-$300M U.S. revenue in 2022 B-NHL & AML; advance in solid tumors Anticipated $245-265M net cash spend; goal to complete drug product facility build

  7. Slide 7: Cash Runway into 2025 Carries Through Multiple Inflections

    Cash Runway into 2025 Carries Through Multiple Inflections 7 Increasing mfg. capabilities Earlier line studies 3L data & BLA Earlier line studies Mfg. process improvements Earlier line studies $1-2B late line global revenue**sLVV Horizon X: Deep Geek Horizon 2: Pipeline Horizon 1: ABECMA® Horizon 0:

  8. Slide 8: ABECMA expected to be $1-2B late line global market opportunity

    ABECMA® expected to be $1-2B late line global market opportunity 8 2021 Launch • Approved on March 26, 2021 • Significant demand to date from patients and physicians • Unaudited US product net revenue of approximately $150M* 2023 and Beyond • Potential to reach patients in earlier line MM • Growing

  9. Slide 9: ABECMA real world experience reinforces paradigm-changing efficacy

    ABECMA real world experience reinforces paradigm-changing efficacy 9 • ASCO 2022 physician poster on real world experience at 11 sites: safety and efficacy in the real world is consistent with KarMMa study • 77% of patients in real world study would not have met the eligibility criteria for KarMMa •

  10. Slide 10: KarMMa-3 pivotal study achieves primary endpoint of mPFS

    KarMMa-3 pivotal study achieves primary endpoint of mPFS Prespecified interim analysis delivers results ahead of original 2023 guidance 10 • The study met its primary endpoint of demonstrating a statistically significant improvement in progression- free survival. • Treatment with ABECMA also showed

  11. Slide 11: KarMMa-3 Study Design

    KarMMa-3 Study Design: Primary Endpoint: PFS; Key Secondary Endpoints: ORR, OS 11 The inclusion criteria of this study is triple class exposed and refractory to their last line of therapy. Limited literature exists in that population with these included, approved standard of care regimens in KarMMa-

  12. Slide 12: Multiple approved autologous CAR T products establish a powerful platform

    Multiple approved autologous CAR T products establish a powerful platform on which to build. We have yet to scratch the surface with ways to embellish engineered T cells to truly capture the potential of cell therapy. 2seventy bio has the toolbox to do this better than anyone. Autologous CAR T cells

  13. Slide 13: R&D engine built to rapidly design, test, learn, & iterate

    R&D engine built to rapidly design, test, learn, & iterate 13 1 2 3 4 5 VECTOROLOGY Maximize payload, innovative design, optimize component co-expression 4 DESIGN LVV mRNA MODALITY Take T cells to the next level, explore alternative chassis 5 ab T CELLS gd T CELLS MANUFACTURING Commoditize LVV, inve

  14. Slide 14: Pipeline

    INDICATION [DRUG] TARGET TECHNOLOGY DISCOVERY STAGE R&D IND-ENABLING PRECLINICAL STUDIES CLINICAL STUDIES APPROVED PRODUCTS Multiple Myeloma [ABECMA] BCMA CAR T cell Multiple Myeloma [ABECMA] BCMA CAR T cell AML-Pediatric [DARIC33] CD33 Drug-Regulated CAR T cell (DARIC) B-NHL [bbT369] Dual B cell ta

  15. Slide 15: bbT369 eliminates challenging tumors

    Patients enrolled 1H 2022 • bbT369 outperformed model CD19 CAR in challenging low antigen expressing tumors in vivo • Data supports potential to overcome resistance and elongate durability of response • Phase I trial permits both CD19 CAR relapsed and naïve patients • Trial intended to be enriched f

  16. Slide 16: CRC-403 study in B-NHL open and enrolling

    CRC-403 study in B-NHL open and enrolling 16 day -5 -2 day 0 day 0-30 day 30 CRC-403: A Phase 1/2 Study of bbT369 in Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) Key Questions / Features QUESTIONS • Is the safety and tolerability of bbT369 in line with prior CAR Ts? • Does bbT369 s

  17. Slide 17: SC-DARIC33: Engineered to kickstart CAR T cell therapy in AML

    How to get there: • Drug regulated CAR Ts overcome the underlying aplasia risk of targeting myeloid cells • Enhance CAR T cell persistence by reducing exhaustive effect of continuous antigen stimulation • Targeting the C2 domain of CD33 designed to deliver target abundance across genotypes limiting

  18. Slide 18: Phase I study (PLAT-08) open and enrolling

    Phase I study (PLAT-08) open and enrolling 18 Study Design: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Key Questions / Features QUESTONS • Do SC-DARIC33 T cells engraft & show activity vs CD33+ve cells? • Is SC-DARIC33 safe and does it drive a clinical

  19. Slide 19: 2seventy's attack on solid tumors designed to address key barriers

    2seventy’s attack on solid tumors designed to address the key barriers to success 19 ONCOLYTIC VIRUSES COMBINATION STRATEGIES ORTHOGONAL MOAs FLIP RECEPTORS SIGNAL 3 DRIVERS GENE EDITING Can we achieve sensitive & multiplex targeting across the full range of target classes? Can we convert suppressiv

  20. Slide 20: MAGE-A4 TCR with a flip receptor to neutralize TGFb

    We have engineered a potent MAGE-A4 TCR with a flip receptor to neutralize TGFb and potentiate T cell activity + Enhanced Potency MAGEA4-CTBR12: Solid tumors 20 What if T cells can deliver heme cancer- like outcomes for patients? Can we substantially enhance the potency of a TCR T cell using a TME s

  21. Slide 21: MUC16/ovarian cancer program: CAR T + pharmaceutical combination strategies

    Our MUC16/ovarian cancer program aims to exploit CAR T + pharmaceutical combination strategies to unlock solid tumors 21 How to get there: • A bold product concept combining an engineered T cell and a potent pharmacologic agent: • CAR targeting a highly prevalent membrane-retained fragment of MUC16

  22. Slide 22: MUC16 CAR T provides in vivo tumor clearance

    Solution Our MUC16 CAR T provides in vivo tumor clearance and can prevent re-growth in a stringent tumor rechallenge model MUC16 CAR shows robust single agent activity in tumor rechallenge model OVCAR3 Ovarian Cancer Xenograft ModelSolution MUC16 CAR exhibits MUC16 ectodomain (“nub”) specificity – d

  23. Slide 23: A MUC16 CAR T cell therapy must overcome several challenges in ovarian cancer

    Key challenges ❑ Hostile/immunosuppressive tumor microenvironment (TME) ❑ Target expression heterogeneity and antigen negative relapse ❑ T cell expansion, persistence & penetration ❑ Healthy tissue liabilities Potential Solutions ✓ Immune checkpoint neutralization, e.g., PD1 ✓ Oncolytic virus-induct

  24. Slide 24: MUC16 program and collaboration with Regeneron

    Our MUC16 program realizes the scientific power of collaboration with Regeneron 24 Tumor targeted co-stimulation Robust toolbox with the potential to unlock deep responses in Ovarian Cancer SCIENCE TRANSLATIONAL MEDICINE Jan 2020 PD-1 inhibitor demonstrating promising results in solid tumors Mouse m

  25. Slide 25: Pipeline

    INDICATION [DRUG] TARGET TECHNOLOGY DISCOVERY STAGE R&D IND-ENABLING PRECLIN. STUDIES CLINICAL STUDIES APPROVED PRODUCTS Multiple Myeloma [ABECMA] BCMA CAR T cell Multiple Myeloma [ABECMA] BCMA CAR T cell AML-Pediatric [DARIC33] CD33 Drug-Regulated CAR T cell (DARIC) B-NHL [bbT369] Dual B cell targe

  26. Slide 26: Horizons focused on long term learning and disruption

    Horizons focused on long term learning and disruption 26 Horizon 0: Launch Company Horizon 1: ABECMA® Horizon 2: Clinical Pipeline Horizon X: Disrupt Spin & Double Down Launch & Scale Liquid Tumors: B-NHL & AML Deep Deep Auto (Very Angry T cell) Focus Team & Burn 3rd Line & Beyond Solid Tumors: MUC1

  27. Slide 27: Biological barriers to achieving deep and durable responses

    What are the biological barriers to achieving deep and durable responses? 27 27 TARGET CLASS Need to improve sensitivity Need to multiplex across target classes TCRs >> CARsLow or reduced target abundance Target loss & heterogeneous expression Poor T cell engraftment and persistence Immunosuppressiv

  28. Slide 28: 2seventy's novel receptor architecture

    2seventy’s novel receptor architecture: a new platform for tumor targeting 28 We have overhauled antigen receptor design and significantly advanced our targeting capabilities… • TCRs have 2- to 3-log higher sensitivity to antigen density • New architecture achieves TCR-like sensitivity to surface ex

  29. Slide 29: F8-GE: Novo Nordisk Partnered Program for Hemophilia A

    HemeA TARGET(S) Endogenous gene promoter trap knock-in of F8 transgene TECH • TSVT megaTAL gene edit • TSVT in vivo grade mRNA production / purification platform • AAV for transgene delivery • Genevant LNPs for hepatocyte delivery INDICATION Hemophilia A STATUS Pre-clinical PARTNER Novo Nordisk, Gen

  30. Slide 30: 2seventy's manufacturing network: Poised to deliver

    2seventy’s manufacturing network: Poised to deliver 30 VELOCITY Enable pipeline speed & decision making to proof-of-concept INNOVATION Multiply our reach, capacity & ability to innovate CAPABILITY Manufacturing partnerships defined by identical goals Secure best-in-class academic partnerships for ex

  31. Slide 31: Leadership

    Leadership Our seasoned team is ready 31 Board of Directors Philip Gregory, D. Phil. Chief Scientific Officer Chip Baird Chief Financial Officer Nick Leschly Chief Kairos Officer* Dan Lynch Board Chair Jenn Snyder Head of Corporate Affairs Nicola Heffron Chief Operating Officer +450 Awesome 270ers K

  32. Slide 32: It's about time™ Time Geeks

    32 It’s about time™ Time Geeks The most committed and passionate geeks driving next gen oncology cell therapeutics

  33. Slide 33: thank you

    —y thank you eseventybio.

2seventy bio — Investor Presentation (August 2022) on 6ix